JP2015512418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512418A5 JP2015512418A5 JP2015503627A JP2015503627A JP2015512418A5 JP 2015512418 A5 JP2015512418 A5 JP 2015512418A5 JP 2015503627 A JP2015503627 A JP 2015503627A JP 2015503627 A JP2015503627 A JP 2015503627A JP 2015512418 A5 JP2015512418 A5 JP 2015512418A5
- Authority
- JP
- Japan
- Prior art keywords
- scopolamine
- ketamine
- disorder
- medicament according
- human subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 42
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 42
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 42
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 42
- 229960003299 ketamine Drugs 0.000 claims description 42
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 42
- 229960002646 scopolamine Drugs 0.000 claims description 42
- 230000037396 body weight Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000024732 dysthymic disease Diseases 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 206010033675 panniculitis Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 208000012672 seasonal affective disease Diseases 0.000 claims description 4
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 4
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 20
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618212P | 2012-03-30 | 2012-03-30 | |
| US61/618,212 | 2012-03-30 | ||
| PCT/US2013/034524 WO2013149102A1 (en) | 2012-03-30 | 2013-03-29 | Compositions comprising scopolamine and ketamine in the treatment of depression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018136350A Division JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015512418A JP2015512418A (ja) | 2015-04-27 |
| JP2015512418A5 true JP2015512418A5 (enExample) | 2015-06-11 |
Family
ID=49261273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503627A Pending JP2015512418A (ja) | 2012-03-30 | 2013-03-29 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
| JP2018136350A Pending JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018136350A Pending JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20150057306A1 (enExample) |
| EP (1) | EP2830604A4 (enExample) |
| JP (2) | JP2015512418A (enExample) |
| WO (1) | WO2013149102A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2911466T3 (es) | 2013-03-15 | 2022-05-19 | Janssen Pharmaceutica Nv | Composición farmacéutica de clorhidrato de S-ketamina |
| WO2016044150A1 (en) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
| US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| JP6845162B2 (ja) | 2015-06-27 | 2021-03-17 | シェノックス・ファーマシューティカルズ・エルエルシー | ケタミン経皮送達システム |
| WO2017087691A1 (en) | 2015-11-17 | 2017-05-26 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
| US10869838B2 (en) | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US12090123B2 (en) | 2017-10-10 | 2024-09-17 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
| WO2019073408A1 (en) | 2017-10-10 | 2019-04-18 | Douglas Pharmaceuticals Ltd. | PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS |
| US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| WO2019094596A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| CA3082423A1 (en) * | 2017-11-14 | 2019-05-23 | Bexson Biomedical, Inc. | Systems, devices, formulations and methods for controlled drug delivery |
| KR20240011237A (ko) | 2017-12-22 | 2024-01-25 | 얀센 파마슈티카 엔브이 | 우울증 치료를 위한 에스케타민 |
| HUE058320T2 (hu) | 2017-12-29 | 2022-07-28 | Celon Pharma Sa | Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén |
| EP3753557B1 (en) | 2018-02-15 | 2025-11-05 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| WO2020028475A1 (en) * | 2018-08-02 | 2020-02-06 | Taiwan Liposome Co., Ltd. | Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof |
| EP3934632A4 (en) | 2019-03-05 | 2022-11-23 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| CN114126596A (zh) * | 2019-05-15 | 2022-03-01 | 贝克森生物医药公司 | 用于皮下注射的氯胺酮制剂 |
| JP7670700B2 (ja) | 2019-10-11 | 2025-04-30 | パイク セラピューティクス インコーポレイテッド | 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物 |
| US20230256004A1 (en) * | 2020-07-09 | 2023-08-17 | Light Aqua Llc | Compositions and methods for treating mood disorders and circadian rhythm sleep disorders |
| CA3198795A1 (en) | 2020-11-18 | 2022-05-27 | Jeffrey Becker | Complexing agent salt formulations of pharmaceutical compounds |
| WO2022132691A1 (en) * | 2020-12-16 | 2022-06-23 | Caamtech, Inc. | Amanita muscaria compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060646C (zh) * | 1993-06-07 | 2001-01-17 | 李举寿 | 戒毒注射液及其制造方法 |
| US8859585B2 (en) * | 2005-05-25 | 2014-10-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Scopolamine for the treatment of depression and anxiety |
| CN101466364A (zh) * | 2006-03-22 | 2009-06-24 | 纽约大学西奈山医学院 | 鼻内施用氯胺酮治疗抑郁症 |
-
2013
- 2013-03-29 WO PCT/US2013/034524 patent/WO2013149102A1/en not_active Ceased
- 2013-03-29 EP EP13767616.9A patent/EP2830604A4/en not_active Withdrawn
- 2013-03-29 US US14/388,410 patent/US20150057306A1/en not_active Abandoned
- 2013-03-29 JP JP2015503627A patent/JP2015512418A/ja active Pending
-
2016
- 2016-03-17 US US15/072,970 patent/US20170042878A1/en not_active Abandoned
-
2018
- 2018-07-20 JP JP2018136350A patent/JP2018184440A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512418A5 (enExample) | ||
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
| WO2011041478A8 (en) | Hematopoietic stem cells for use in the treatment of a kidney injury | |
| JP2013541583A5 (enExample) | ||
| WO2014184576A3 (en) | Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| JP2017524721A5 (enExample) | ||
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| JP2017061488A5 (enExample) | ||
| HK1222585A1 (zh) | 用於提供疼痛减轻和麻醉的二氢埃托啡 | |
| MX2010006724A (es) | Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios. | |
| WO2014100679A8 (en) | Stimulation and enhancement of regeneration of tissues | |
| JP2010538054A5 (enExample) | ||
| JP2016504361A5 (enExample) | ||
| JP2015512923A5 (enExample) | ||
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности | |
| CN104667073A (zh) | 治疗神经衰弱的中药 | |
| Naik et al. | Comparative study of acupressure wristband versus palonosetron for prophylaxis of postoperative nausea and vomiting in elective laparoscopic cholecystectomy under general anaesthesia | |
| WO2009113810A3 (ko) | 알레르기질환 및 자가면역질환의 예방 또는 치료를 위한 약학적 조성물, 그의 용도 및 알레르기질환 및 자가면역질환의 예방 또는 치료 방법 | |
| JP2015512439A5 (enExample) |